Related Experiment Video

Updated: Oct 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with

M H Davidson1, E A Stein, D B Hunninghake

  • 1Chicago Center for Clinical Research, Chicago, IL, USA.

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|February 24, 2001
PubMed

Insights

The 80 mg dose of simvastatin significantly lowers low-density lipoprotein cholesterol (LDL-C) more than the 40 mg dose. This higher dose of simvastatin is safe and well-tolerated for hypercholesterolemia treatment.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Aggressive low-density lipoprotein cholesterol (LDL-C) targets are established for hypercholesterolemia treatment.
  • Larger LDL-C reductions correlate with decreased coronary heart disease events.

Purpose of the Study:

  • Evaluate the efficacy and safety of simvastatin 80 mg, a new maximum dose.
  • Compare simvastatin 80 mg against 40 mg in hypercholesterolemic patients.

Main Methods:

  • Combined results from 4 pivotal, randomized, double-blind, controlled studies.
  • 1936 hypercholesterolemic patients received simvastatin 40 mg or 80 mg for 36-48 weeks.

Main Results:

  • Simvastatin 80 mg demonstrated significantly greater LDL-C reduction (-45.7%) versus 40 mg (-39.8%) at 24 weeks (p < 0.001).
  • The 80 mg dose also yielded greater reductions in total cholesterol and triglycerides.
  • Both doses were well-tolerated, with infrequent hepatic transaminase elevations and myopathy; safety profiles were comparable between doses and across demographics.

Conclusions:

  • Simvastatin 80 mg offers superior LDL-C and triglyceride lowering compared to simvastatin 40 mg.
  • Simvastatin 80 mg exhibits an excellent safety and tolerability profile for managing hypercholesterolemia.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...